Nebenwirkungen · Enhertu
Enhertu 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-144549 · Präparat HOS-099200
Enhertu 5.4 mg/kg in combination with pertuzumab In patients treated with Enhertu 5.4 mg/kg in combination with pertuzumab (n = 431), 17.4% were 65 years or older and 3% were 75 years or older. The incidence of Grade 3-4 adverse reactions observed in patients aged 65 years or older was 52% and in younger patients was 55.1%. The incidence of fatal adverse reactions was 4.0% in patients aged 65 years or older and 1.1% in patients younger than 65 years of age. The incidence of adjudicated ILD/pneumonitis was 20.0% in patients aged 65 years or older and 11.5% in patients younger than 65 years of age.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T16:27:00Z · SHA-256 3c4c744afc1ef29bbcad254e39bd7fd8b4be34bb4ddecf254258c2ab2c9863c8 · Passage c1d841289bf8a6c21119f965e9a6ca8add71d3ad9932a86541e73a8fca2a503d · Zeichen 32983–33586 im Abschnitt